PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This edition of PxWire includes a feature on the new momentum to end the AIDS epidemic in light of the recent HPTN 052 results; an exploration of the progress in AIDS vaccine research and the need for evolving trial designs to accommodate new trial results such as those from HPTN 052 and iPrEx; and, as always, a centerspread with an updated timeline of biomedical HIV prevention efficacy trials and a world map showing where various strategies are being tested.
Px Wire July-September 2011, Vol. 4, No. 3
2010 AVAC Report: Turning the Page (Thai translation)
The AVAC 2010 Report, Turning the Page, highlights that the biomedical prevention field is entering the next chapter of its development. The past year brought the first evidence, from the Thai Prime-Boost trial, that an AIDS vaccine could prevent HIV in humans, as well as significant preclinical findings around potent, HIV-specific neutralizing antibodies.
At the same time, two microbicide trials testing the candidate PRO 2000 yielded seemingly different, but ultimately disappointing results, and the field now prepares for the release of results from CAPRISA 004, the first ARV-based microbicide effectiveness trial.
Px Wire April-June 2010, Vol. 3, No. 2
PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. Highlights in this issue include: next steps in AIDS vaccine trials in the post-Thai vaccine trial (RV144) era; “test and treat” approach for prevention presented at CROI; a preview of AVAC Report 2010; information on the Microbicides 2010 Pre-Conference Advocacy Workshop; new funding for advocacy related to MSM and prevention research; six new clinical trials looking at enhanced prevention strategies.
Px Wire January-March 2010, Vol. 3, No. 1
PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. Highlights in this issue of PxWire include updates on: the results from MDP 301, a trial of the microbicide PRO 2000, which lay to rest its prospect as a viable microbicide; CDC’s newly modified PrEP trial (TDF2 in Botswana), which changed its status as an efficacy trial to a safety and behavioral study; the evolving effort to understand the Thai prime-boost AIDS vaccine results; recent NIH grants that nearly double global spending on rectal microbicides; and a timeline of 2010 trial milestones—what trial results are expected and what new studies are scheduled to commence?
Anticipating the Results of the Phase III AIDS Vaccine Trial in Thailand
A 2009 document discussing the RV144 vaccine trial in advance of efficacy data. It provides background information on the vaccine candidate and trial design, and explores potential scenarios for the results.
Px Wire January-March 2009, Vol. 2, No. 1
PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. Highlights in this issue of PxWire include a report on data from the Step vaccine trial and animal studies of relevance to the proposed HVTN 505 trial of the NIH Vaccine Research Center DNA-Ad5 combination strategy presented at the Keystone Symposium on HIV prevention–an annual meeting focused on basic and preclinical science. This issue also reviews newly launched trials, lays out this year’s upcoming trial milestones, and gives information on ordering the 2009 AVAC report on the prevention research field, to be released in May.
Px Wire October-December 2008, Vol. 1, No. 4
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. Highlights of this year-end issue include: AVAC’s take on the year in prevention research; an update on the proposed AIDS vaccine trial HVTN 505; news on the female condom and microbicide trials.
Px Wire July-September 2008, Vol. 1, No. 3
PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. Highlights in this issue of PxWire include a discussion of the no-go decision on the proposed PAVE 100 vaccine trial (though the candidate may yet be tested), updates on women’s input into male circumcision for HIV prevention, and AVAC’s take on indelible moments and themes from the International AIDS Conference in Mexico City in August.
Px Wire April-June 2008, Vol. 1, No. 2
PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. Highlights in this issue of PxWire include an update on the ongoing discussion regarding the proposed PAVE 100 vaccine trial, details on the first microbicide trial in pregnant women, a Mexico City preview, and notes on two recently released resources for the field, AVAC Report 2008: The Search Must Continue and the Global Campaign for Microbicides’ Microbicides Essentials online learning tool.
Px Wire Abril-Junio 2008, Vol. 1, No. 2 (en español)
PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. Highlights in this issue of PxWire include an update on the ongoing discussion regarding the proposed PAVE 100 vaccine trial, details on the first microbicide trial in pregnant women, a Mexico City preview, and notes on two recently released resources for the field, AVAC Report 2008: The Search Must Continue and the Global Campaign for Microbicides’ Microbicides Essentials online learning tool.